Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis

详细信息    查看全文

• 作者：Chiara Rosso^a ; ¹ ; ^{crosso3@cittadellasalute.to.it" class="auth_mail" title="E-mail the corresponding author} ; ^{chiara.rosso84@tiscali.it" class="auth_mail" title="E-mail the corresponding author} ; Gian Paolo Caviglia^a ; ¹ ; Maria Lorena Abate^a ; Ester Vanni^a ; ^b ; Lavinia Mezzabotta^a ; ^b ; Giovanni Antonio Touscoz^b ; Antonella Olivero^a ; Andrea Marengo^a ; ^b ; Mario Rizzetto^a ; ^b ; Elisabetta Bugianesi^a ; ^b ; Antonina Smedile^a ; ^b
• 关键词：Chronic liver disease ; Cytokeratin 18-Asp396 ; Liver stiffness
• 刊名：Digestive and Liver Disease
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：48
• 期：1
• 页码：55-61
• 全文大小：580 K

文摘

The combination of non-invasive markers for the detection of fibrosis in patients with chronic liver diseases is still a matter of debate.

Aims

To test the performance of cytokeratin18-Aspartate396 alone or in combination with transient elastography as a marker of fibrosis, compared to liver biopsy as gold standard.

Methods

In 259 prospectively enrolled patients with chronic liver diseases, clinical, biochemical, and histological features were assessed. Serum cytokeratin18-Aspartate396 and Fibroscan were performed within 6 months prior to liver biopsy.

Results

Cytokeratin18-Aspartate396 levels predicted both significant and advanced fibrosis in non-alcoholic fatty liver disease group, correctly identifying 83.7% and 80.8% of cases, respectively. Liver stiffness performed best in predicting severe fibrosis in patients with chronic viral infection, correctly identifying 78.7% of chronic hepatitis B and 88.6% of chronic hepatitis C subjects. The combination of cytokeratin18-Aspartate396 and liver stiffness improved their diagnostic performance for the detection of significant and advanced fibrosis in non-alcoholic fatty liver disease group, only (sensitivity = 78.3%, specificity = 90.7%; sensitivity = 91.7%, specificity = 71.6%, respectively).

Conclusion

Cytokeratin18-Aspartate396 and liver stiffness can improve the non-invasive prediction of significant and advanced fibrosis in patients with non-alcoholic fatty liver disease, while in hepatitis B and C virus infected patients their combined use had no advantage over the diagnostic accuracy of transient elastography alone.